rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
|
31123683 |
2019 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia.
|
28602946 |
2017 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Considerable effort is being made to understand the role of JAK2(V617F) at the MPN initiation and to clarify the pathogenesis and apoptosis resistance in CML, PV, ET and PMF patients.
|
27282563 |
2016 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Missense mutations of A300V, V402M, and R415H in LNK were found in 8 patients including ET (4 cases, all combined with JAK2-V617F mutation), PV (2 cases, one combined with JAK2-V617F mutation), PMF (one case, combined with JAK2-V617F mutation) and CML (one case, combined with BCR/ABL1 fusion gene).
|
27111338 |
2016 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
One case of CML developed ET-like morphology and had JAK2 V617F detected while in molecular remission for CML.
|
26754830 |
2016 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
We studied samples from 1088 persons with myeloproliferative neoplasms (MPNs) including 421 JAK2(V617F) negative subjects with ET, PMF, polycythemia vera (PV), chronic myeloid leukemia (CML) and hyper-eosinophilic syndrome (HES).
|
25860380 |
2015 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
The JAK2 V617F mutation is common in patients with Philadelphia-negative chronic myeloproliferative neoplasms, but few cases of the JAK2 V617F mutation have been described in Philadelphia-positive chronic myeloid leukemia (CML) patients.
|
24293258 |
2014 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Previous studies have reported FLT3 mutation in as many as 9.2% of myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), as well as in chronic myelogenous leukemia, that are negative for the JAK2 V617F gene mutation; no FLT3 mutation has been found in JAK2-positive MPNs, suggesting that the mutations are mutually exclusive.
|
23846442 |
2013 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
In light of the findings from previous reports, screening for the JAK2-V617F mutation should be considered for any Ph(+) CML patients with thrombocytosis, leukocytosis, or erythrocytosis at diagnosis and for patients who subsequently develop thrombocytosis, leukocytosis, or erythrocytosis during follow-up, even for CML patients in complete cytogenetic response and major molecular response.
|
23613267 |
2013 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
However it is not so easy, because iPSCs from hematological malignancies have been established only from myeloproliferative neoplasms including chronic myelogenous leukemia (CML) and JAK2-V617F mutation-positive polycythemia vera (PV). iPSC technology has great potential to promote oncology research based on patient samples.
|
23807288 |
2013 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
LCN-2 mRNA showed a near 50-fold increase in expression, accompanied by down-regulation of SLC22A17, coinciding with increase in BCR-ABL transcripts, loss of JAK2-V617F and change of clinical phenotype from polycythaemia vera to chronic myeloid leukaemia.
|
21950422 |
2012 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
These results demonstrate that STAT5a/b is essential for the induction of CML-like leukemia by BCR-ABL1 and of polycythemia by JAK2(V617F), and validate STAT5a/b and the genes they regulate as targets for therapy in these MPNs.
|
22234689 |
2012 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Chronic myeloproliferative neoplasms (MPN) are clonal disorders of hematopoietic stem cells, which fall into distinct categories based on a number of characteristics including the presence of the BCR-ABL1 gene fusion (chronic myelogenous leukemia) or the JAK2(V617F) mutation (polycythemia vera, primary myelofibrosis, and essential thrombocythemia).
|
22847163 |
2012 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Abnormalities of tyrosine kinase proteins are well recognised in myeloid malignancies, mutation in the cytoplasmic tyrosine kinase JAK2 (V617F) is key in the pathogenesis of myeloproliferative neoplasms, and translocations involving ABL key in the development of chronic myeloid leukaemia.
|
21722956 |
2011 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
The association of V617F JAK2 expression levels with disease behavior has not been studied in patients with nonchronic myelogenous leukemia (CML) myeloproliferative disease (MPD).
|
19254349 |
2010 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Moreover, we identified IDH mutations in 2 JAK2 V617F myeloproliferative neoplasias (n = 96), a single case of acute lymphoblastic leukemia (n = 96), and none in chronic myeloid leukemias (n = 81).
|
20538800 |
2010 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
And finally, Will the benefits conferred by current or future JAK2(V617F) inhibitors equal or even surpass the clinical success that has resulted from the use of tyrosine kinase inhibitors in CML?
|
19641523 |
2009 |
rs77375493
|
JAK2;INSL6
|
Myeloid Leukemia, Chronic
|
|
0.100 |
GeneticVariation |
BEFREE |
Abnormal nuclear megakaryocytic staining for phospho-STAT5 (pSTAT5) correlates with JAK2 V617F mutational status in non-chronic myelogenous leukemia chronic myeloproliferative disorders.
|
18479730 |
2008 |